Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Published Online
on December 27, 2007

Arteriosclerosis, Thrombosis, and Vascular Biology. 2007
Published online before print December 27, 2007, doi: 10.1161/ATVBAHA.107.159483
A more recent version of this article appeared on March 1, 2008
This Article
Right arrow Full Text (PDF)
Right arrow Additional Materials
Right arrow All Versions of this Article:
28/3/534    most recent
ATVBAHA.107.159483v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pape, R.
Right arrow Articles by Schrör, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pape, R.
Right arrow Articles by Schrör, K.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH

Submitted on July 20, 2007
Accepted on December 11, 2007

Transcriptional Inhibition of Protease-Activated Receptor-1 Expression by Prostacyclin in Human Vascular Smooth Muscle Cells

Robert Pape ; Bernhard H. Rauch *; Anke C. Rosenkranz ; Gernot Kaber ; and Karsten Schrör

From the Institut für Pharmakologie und Klinische Pharmakologie, Heinrich-Heine-Universität Düsseldorf, Germany.

* To whom correspondence should be addressed. E-mail: rauchb{at}uni-duesseldorf.de.

Objective—Stimulation of protease-activated receptor-1 (PAR-1) by thrombin causes vascular smooth muscle cell (SMC) mitogenesis and has been implicated in the vascular response to injury. Vascular injury is also associated with enhanced formation of PGE2 and PGI2 (prostacyclin). This study investigates whether PGI2 and PGE2 modify the expression of PAR-1 and the cellular response to thrombin in human SMC.

Methods and Results—The PGI2-mimetic iloprost (1 to 100 nmol/L) attenuated mRNA, total protein, and cell surface expression of PAR-1. This was associated with inhibition of thrombin-induced mitogenesis and migration. Comparable inhibition of PAR-1 expression was observed with the selective IP-receptor agonist cicaprost, the adenylyl cyclase activator forskolin, the phosphodiesterase inhibitor isobutylmethylxanthine and the PKA activator dibutyryl-cAMP. Similar effects of PGE2 required micromolar concentrations. The specific PKA-inhibitor Myr-PKI prevented PAR-1 downregulation by iloprost. The potential role of Rho family GTPases in PAR-1 regulation was also investigated. Iloprost decreased Rac1 mRNA and the Rac1 inhibitor NSC23766 mimicked the inhibitory effects of iloprost on PAR-1 protein—but not mRNA. The Rho kinase inhibitor Y27632 did not influence PAR-1 expression.

Conclusions—IP-receptor agonists may limit the mitogenic actions of thrombin in human SMC by downregulating PAR-1 via modulation of cAMP-/PKA- and Rac1-dependent signaling pathways.


Key words: protease-activated receptor-1 (PAR-1) • smooth muscle • thrombin • prostaglandins • Rac1




This article has been cited by other articles:


Home page
Cardiovasc ResHome page
A. C. Rosenkranz, B. H. Rauch, K. Freidel, and K. Schror
Regulation of protease-activated receptor-1 by vasodilatory prostaglandins via NFAT
Cardiovasc Res, June 11, 2009; (2009) cvp163v2.
[Abstract] [Full Text] [PDF]